Compare Davita Inc (DVA) vs Grab Holdings Ltd. (GRAB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Grab Holdings Ltd. — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while Grab Holdings Ltd. trades at $3.13 (market cap $12.72B). The key difference: Davita Inc and Grab Holdings Ltd. are close in size by market cap, and Davita Inc is trading nearer its 52-week high, Grab Holdings Ltd. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Grab Holdings Ltd. for 94 Days on average.
| DVA | GRAB | |
|---|---|---|
Market Cap | $11.29B | $12.72B |
Volume | 582,204 | 65,352,859 |
Sector | Health | Technology |
52-Week High | $240.96 | $6.17 |
52-Week Low | $103.87 | $2.80 |
Typical Hold Time | 113 Days | 94 Days |
Enterprise Value | $24.01B | $8.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
GRAB trades at $3.08, up 0.33% with bearish technical signals but strong fundamentals. The company achieved profitability in 2025 with $268M net income and has beaten earnings estimates for three consecutive quarters. Recent news highlights a $30M CEO share purchase and acquisition of Atome Financial, signaling management confidence and financial services expansion.
GRAB presents a turnaround story with improving profitability and analyst support (91.7% buy ratings), though technical indicators remain bearish. Key risks include aggressive capital deployment and regional regulatory challenges. The stock offers growth potential but requires monitoring of execution risks and competitive pressures in Southeast Asia.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →
